Abi Manesh

Abi Manesh

Auto-generated profile, based on publicly available information

Abi Manesh

Department of Infectious Diseases, Christian Medical College, Vellore, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2019 in Mycoses
Verified
Journal Article
Closed access
PDF file
AMAbi Manesh
Abi Manesh
Priscilla RupaliPriscilla Rupali
Priscilla Rupali
MSMaire O. Sullivan
Maire O. Sullivan
PMPromila Mohanraj
Promila Mohanraj
VRVedantam Rupa
Vedantam Rupa
JMJoy Sarojini Michael
Joy Sarojini Michael

24 August 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
KBKundakarla Bhanuprasad
Kundakarla Bhanuprasad
AMAbi Manesh
Abi Manesh
EDEmily Devasagayam
Emily Devasagayam
LVLalee Varghese
Lalee Varghese
LCLisa Mary Cherian
Lisa Mary Cherian
GVGeorge M Varghese
George M Varghese
This study was performed to assess the risk factors driving the epidemic of coronavirus disease 2019 (COVID-19)-associated mucormycosis (COVID–Mucor) in India that has accompanied the COVID-19 pandemic, particularly during the second wave. Risk factors were analysed among 164 participants: 132 COVID–Mucor (cases) and 32 non-COVID–Mucor (controls). Data from a prospective cohort study of mucormycosis over a period of 1 year were used. Diabetes mellitus remained a significant risk factor in both groups (97%), while uncontrolled diabetes mellitus (odds ratio (OR) 4.6; P = 0.026) and newly detected diabetes (OR 3.3; P = 0.018) were more common among the cases. Most patients with COVID–Mucor had mild COVID-19. Steroid use, often unwarranted, was highly associated with COVID–Mucor after adjusting for other risk factors (OR 28.4; P = 0.001). Serum ferritin was significantly higher (P = 0.041), while C-reactive protein was not, suggesting that alterations in iron metabolism may predispose to COVID–Mucor. Oxygen was used only in a small minority of patients with COVID–Mucor. The in-hospital mortality in both groups was low. In conclusion, the Indian COVID–Mucor epidemic has likely been driven by a convergence of interlinked risk factors: uncontrolled diabetes mellitus, unwarranted steroid use, and perhaps COVID-19 itself. Appropriate steroid use in patients with severe COVID-19 and screening and optimal control of hyperglycaemia can prevent COVID–Mucor.

2 April 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
BVBalaji Medical Veeraraghavan
Balaji Medical Veeraraghavan
ESEunjeong Shin
Eunjeong Shin
YBYamuna Devi Bakthavatchalam
Yamuna Devi Bakthavatchalam
AMAbi Manesh
Abi Manesh
DDDilip Dubey
Dilip Dubey
Robert BonomoRobert Bonomo
Robert Bonomo
In the ATTACK Phase 3 trial examining the efficacy of sulbactam (SUL)/durlobactam (DUR) to treat primarily Acinetobacter baumannii complex (ABC) infections, imipenem (IPM)/cilastatin was added as a common therapy to both the SUL/DUR and the comparator colistin arms. This raised the question of whether the use of IPM in the SUL/DUR arm of the study influenced the efficacy of SUL/DUR. To investigate this issue on a microbiological and molecular level, we performed static concentration time-kill studies and molecular modeling of binding of SUL to PBP1a and PBP3, IPM to PBP1a, PBP2, and PBP3, and DUR to OXA-23 and OXA-51. The time-kill studies performed using carbapenemase- and non-carbapenemase-producing isolates demonstrated synergy between SUL and IPM in the presence of DUR, supporting the notion that the efficacy of the SUL/DUR arm against Acinetobacter spp. in the ATTACK trial was enhanced by the addition of IPM. We also hypothesize that the protection of SUL and IPM from OXA carbapenemases by DUR enabled IPM and SUL to synergistically deactivate multiple PBPs (“target redundancy”). Docking simulations supported the favorable binding of SUL to PBP1a and PBP3, resulting in the formation of acyl–enzyme complexes. Molecular docking analysis of OXA carbapenemase enzymes with DUR also revealed favorable interactions. Although clinical trials are warranted, these analyses provide mechanistic support for the addition of IPM to SUL/DUR.

13 April 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
YBYamuna Devi Bakthavatchalam
Yamuna Devi Bakthavatchalam
DEDivyaa Elangovan
Divyaa Elangovan
SJSubha Vajjiravelu Jaganathan
Subha Vajjiravelu Jaganathan
NSNivedhana Subburaju
Nivedhana Subburaju
ASAbirami Shankar
Abirami Shankar
BVBalaji Medical Veeraraghavan
Balaji Medical Veeraraghavan
The study revealed the differential ability of cefepime/taniborbactam and cefepime/zidebactam in tackling carbapenemase-producing Indian clinical isolates that also harbored additional mechanisms of resistance. NDM-expressing E. coli with 4-amino-acid insert in PBP3 are predominately resistant to cefepime/taniborbactam, while the β-lactam enhancer mechanism-based cefepime/zidebactam showed consistent activity against single- or dual-carbapenemase-producing isolates including E. coli with PBP3 inserts.

1 July 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
AMAbi Manesh
Abi Manesh
RBRohit Barnabas
Rohit Barnabas
SMSunithi Mani
Sunithi Mani
RKRajiv Karthik
Rajiv Karthik
OAO.C. Abraham
O.C. Abraham
GVGeorge M Varghese
George M Varghese
The clinical syndrome in symptomatic HIV associated CNS viral escape is poorly defined. We attempted to describe the clinical syndrome, laboratory profile, radiological features and outcomes of HIV infected patients with symptomatic central nervous system (CNS) viral escape in our study. This is a retrospective study were adult patients with HIV infection on cART admitted with a diagnosis of CD8 encephalitis or CNS viral escape in a large teaching hospital in South India was identified. The mean age of the eleven patients included in the study was 37.5 years. Most patients had received almost a decade of antiretroviral treatment at diagnosis (mean: 11.18 years). All patients presented with global cerebral syndrome. Cognitive decline, tremors, and headaches were common manifestations. All patients had lymphocytic pleocytosis (mean cell count: 44.63 cells/ml; lymphocyte percentage: 94.81%) with elevated protein (mean: 125.36 mg/dl). All patients were on boosted protease inhibitors (81.8% on Atazanavir and 18.18% Lopinavir). All except one patient was on Tenofovir and lamivudine combination therapy. White matter changes and deep brain nuclei involvement were common. Most patients required a change of cART to regimens with better CNS penetration and suppression of the resistant virus in the plasma and improved. CNS viral escape should be considered as a differential among patients on Atazanavir presenting with non-focal cerebral syndrome and CSF lymphocytic pleocytosis.

25 November 2016 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AMAbi Manesh
Abi Manesh
BVBalaji Medical Veeraraghavan
Balaji Medical Veeraraghavan
NRNaveen Kumar Devanga Ragupathi
Naveen Kumar Devanga Ragupathi
Priscilla RupaliPriscilla Rupali
Priscilla Rupali
Typhoid fever remains a serious problem in many developing countries. Due to resistance to multiple first line drugs, azithromycin has evolved as an important drug in the treatment of typhoid. While therapy with azithromycin is highly effective, no clinically validated mean inhibitory concentration (MIC) break points or disc diffusion cutoff guidelines are available so far. We describe an Indian adult with clinical and microbiological failure to azithromycin despite low azithromycin MIC.